Twist Bioscience (TWST) Investor Day 2026 summary

Technology Platform Advancements

• Achieved industry-leading DNA synthesis with 500-mer length and error rates as low as 1 in 3,000 base pairs, enabling production of 32 million oligos per day and supporting complex gene and protein applications.

• Expanded product lines over five years, including Express Genes, ultra complex genes, and advanced NGS panels, leveraging improved synthesis and automation.

• Integrated automation systems reduced production footprint by 80% and doubled output, enabling rapid, scalable manufacturing for genes, proteins, and NGS products.

• Continuous process improvements led to a 60% reduction in synthesis costs and a 73% reduction in turnaround time from 2023 to 2026.

• Operational excellence initiatives delivered tens of millions in savings and quadrupled oligo synthesis capacity with the same headcount.

AI-driven Drug Discovery and Customer Impact

• AI-enabled workflows drive rapid, large-scale antibody and protein engineering, with flexible data and product delivery tailored to customer needs.

• Collaborations with leading AI and pharma companies have enabled success rates in antibody design to rise from 0.1% to 16% in one year, with over 200,000 proteins expressed and 7 million data points generated.

• Customers leverage the platform for both pilot and large-scale studies, with iterative cycles of model building, training, and therapeutic candidate optimization.

• AI-driven demand is fueling triple-digit revenue growth and expanding the addressable market for antibody discovery and protein expression services.

• The platform supports a broad range of modalities, including bispecifics and oligonucleotide therapeutics, with customers like Chai Discovery, Elsie Bio (GSK), and Samsara Eco highlighting transformative impacts.

Market Outlook and Strategic Positioning

• The DNA market is projected to remain flat at $2 billion by 2030, while antibody drug discovery and AI-driven services are expected to drive significant growth.

• AI is assumed to enable multiple winning models and successful drug discovery, expanding the market for both DNA synthesis and downstream applications.

• The company’s strategy centers on offering a full, customizable menu of high-throughput, high-quality solutions, meeting diverse customer requirements across pharma, biotech, and sustainability sectors.

• Customer feedback and partnerships emphasize the importance of speed, flexibility, and data quality in maintaining competitive advantage.

• Expansion into enzyme engineering for sustainability demonstrates the platform’s versatility beyond healthcare, enabling breakthroughs in circular biomanufacturing and plastics recycling.